Physician

Sean Adam Fischer, M.D.

According to 2025 Medicare claims, Sean Fischer, M.D. (NPI: 1801842943) practices hematology/oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is PROVIDENCE SAINT JOHNS MEDICAL FOUNDATION (NPI: 1770093734; TIN: 814542216) and primary practice location at 90404-2182. Fischer is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Fischer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 900 traditional Medicare patients, billed 336,405 HCPCS/CPT codes, and received $6,460,563 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,715 prescription claims across 282 beneficiaries totaling $4,909,900 in drug costs, led by Revlimid (Lenalidomide). DME data shows 50 claims. Open Payments data shows 4 records totaling $709. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,289,934 to $6,460,563. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,610,109 and ending at $4,909,900. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,193 to $1,258.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	493	126,888	$1,289,934
2016	597	94,141	$1,551,151
2017	660	134,819	$1,919,355
2018	683	154,874	$2,513,040
2019	686	143,371	$3,039,698
2020	657	158,762	$2,867,446
2021	713	198,444	$3,934,477
2022	821	278,976	$4,648,290
2023	835	280,824	$5,528,273
2024	900	336,405	$6,460,563

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	129	1,247	$1,610,109
2016	161	1,221	$1,746,870
2017	185	1,282	$2,838,545
2018	160	802	$1,330,908
2019	191	935	$1,286,388
2020	182	915	$1,682,068
2021	199	978	$2,472,935
2022	224	1,210	$1,969,532
2023	252	1,314	$2,315,880
2024	282	1,715	$4,909,900

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	126	$5,675
2016	N/R	63	$38,403
2017	N/R	36	$14,988
2018	N/R	28	$3,723
2019	N/R	N/R	N/R
2020	N/R	65	$4,504
2021	N/R	39	$1,889
2022	11	76	$3,074
2023	N/R	86	$20,279
2024	N/R	50	$1,346

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	628	1,374	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	768	1,886	$14
80053	Blood test, comprehensive group of blood chemicals	503	1,471	$10
36415	Insertion of needle into vein for collection of blood sample	586	1,659	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	612	2,574	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	47	1,316	$852,610
Lenalidomide	Lenalidomide	42	1,176	$581,432
Calquence	Acalabrutinib Maleate	25	750	$379,676
Idhifa	Enasidenib Mesylate	12	360	$354,087
Tagrisso	Osimertinib Mesylate	19	570	$345,221

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$894
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$452

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$709	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sean Adam Fischer, M.D.?

Tedicare shows public-source Medicare data for Sean Adam Fischer, M.D. (NPI 1801842943), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sean Adam Fischer, M.D. have ACO affiliation data?

Sean Adam Fischer, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Sean Adam Fischer, M.D.?

Sean Adam Fischer, M.D. is linked to PROVIDENCE SAINT JOHNS MEDICAL FOUNDATION (billing NPI 1770093734) in the available physician profile data.

Does Sean Adam Fischer, M.D. have Open Payments data?

Sean Adam Fischer, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.